-
February 20, 2017
Tchaikapharma High Quality Medicines Inc. received another Marketing Authorization by the Bulgarian Drug Agency with which the company updated its list of injectable products. The new oncological drug product is called Pemetrexed-Tchaikapharma 500 mg powder for concentrate for solution for infusion and is used in the treatment of malignant pleural mesothelioma and non-small cell lung cancer.
Еаch phial contains the active substance Pemetrexed (Pemetrexed disodium hemipentahydrate) and is subject to medical prescription.
ATC code: L01BA04
-
February 9, 2017
Bortezomib-Tchaikapharma 3.5 mg powder for solution for injection is Tchaikapharma High Quality Medicines’ newest medicinal product which obtained a Marketing Authorisation by the Bulgarian Drug Agency in the beginning of February 2017. The active substance contained is Bortezomib (as a mannitol boronic ester).
The medicinal product is subject to medical prescription.
ATC code: L01XX 32
-
February 2, 2017
Lidocaine-Tchaikapharma is the company’s newest product with a marketing authorization issued by BDA
Lidocaine-Tchaikapharma 10 mg and 20 mg solution for injection is Tchaikapharma’s newest product which has obtained a Marketing Authorization issued by the Bulgarian Drug Agency.
Therapeutic indications:
- For local anesthesia in surgery, dentistry, urology, cardiology, ophthalmology, otorhinolaryngology and other invasive instrumental investigations.
- For the treatment of ventricular arrhythmias, including after myocardial infarction and cardiac surgery interventions.
ATC code: C01BB 01, N01BB 02
-
December 23, 2016
-
November 23, 2016
The renowned business ranking “300 Business Leaders in Bulgaria” for one more year honoured Tchaikapharma High Quality Medicines Inc. as one of the most profitable and influential companies in Bulgaria.
The ranking’s fifth edition prepared by analysts from ICAP Group brings together the most successful companies in the country for the past year 2015, based on the criterion “Earnings before interest, taxes, depreciation and amortization (EBITDA)”.
This year Tchaikapharma marked alike a growth on the paramount indicators ‘profit’ (13%) and ‘equity’ (15%). In 2015, EBITDA-profit of the company rose by nearly 11% over the previous year.
These positive trends determine the high market capitalization of the company amounting to approximately 372.5 million leva (as of 21/11/2016).